5 Questions Biopharma IT Leaders Should Ask Before Approving AI in Their Data Environment
For biopharma IT, security, and data platform leaders, approving AI is not just a product decision; it is a data governance, architecture, and risk decision. If you are being asked to approve an AI capability from a vendor, you should be asking hard questions before anything touches production data to help maintain data integrity in the pharmaceutical industry.
Here are the questions we would ask in your seat, and how we are answering them as we build our AI tool inside the ICyte® Platform.
1. Where Does the Data Actually Go?
The first question for any AI feature is whether your data moves. Many AI add-ons work by copying data out to the vendor's service or a third-party API, which means a new data flow to review, a new processor agreement, and a new surface to secure. Our AI tool takes the opposite approach: the AI comes to the data. It runs inside the same Snowflake environment where ICyte® data already lives, behind the same security perimeter you have already reviewed. No new pipelines carrying your data somewhere else, and no copies accumulating in a system you did not approve.
2. Does the AI Respect Your Access Model?
AI should inherit your access controls, never bypass them. The ICyte® architecture is database-per-tenant, so each customer's data lives in its own database with an identical, versioned structure. Our AI tool access is granted through dedicated roles scoped to a single client and environment, and the AI can query exactly what that role permits and nothing else. That gives your security team a clean answer to the audit question of what the AI can see: precisely what the role grants, provable from the grant itself.
3. Is the AI-Ready Data Productized, or Is It a Science Project?
Getting data AI-ready takes real engineering, and how a vendor does it tells you a lot. If it is a pile of one-off ETL jobs maintained by hand, then every schema change is a risk and every new customer is a special case. We build the denormalized reporting layers our AI tool relies on as Snowflake Dynamic Tables that are part of the product deployment itself. They ship through the same pipeline framework as the rest of the platform, identical across every tenant, covered by the same change management. When the product evolves, the AI's data layer evolves with it, not weeks later when someone remembers to update a script.
4. What Does It Cost to Run AI ?
LLM compute is a real line item, and unmanaged token spend surprises people. Two things matter here.
First, attribution: because our AI tool runs under dedicated roles, its usage and spend are tracked separately from integration, reporting, and managed services workloads, per client, so cost is visible instead of smeared across the account.
Second, architecture: a well-designed platform does not ask an LLM to compute what deterministic logic already computes. ICyte® carries years of validated business logic, and our AI tool uses it rather than re-deriving it token by token. That is cheaper, and it is also more accurate. We are building guardrails on token consumption as well, so a runaway query pattern cannot become a runaway bill.
5. How Do You Know AI Answers Are Right?
This is the question that matters most and gets asked least. Our answer has layers. The semantic layer gives our AI tool trusted metric definitions, curated relationships between data sets, and validated queries for recurring questions, so routine answers rest on tested ground rather than improvisation. Beyond that, agentic analyses are treated like software: scoped, tested against real history, and released with the same discipline as any other part of the platform, with human review wherever the risk warrants it. If a vendor cannot describe their validation process at that level of specificity, that is your answer.
About IntegriChain
IntegriChain delivers biopharma’s only comprehensive data-driven commercialization platform from strategy to operational execution, connecting the commercial, financial, and operational dimensions of drug access and profitability. Our ICyte® Platform integrates technology, data, consulting, and managed services to unify critical workflows, replacing manual processes with integrated analytics and precision controls.
Biopharma relies on IntegriChain to optimize patient access and net revenue performance, reduce leakage, and strengthen compliance, ensuring every life-changing therapy reaches patients with speed, affordability, and sustainability. Backed by Nordic Capital, a leading sector-specialized private equity investor with a broad portfolio in healthcare and technology.
IntegriChain is headquartered in Philadelphia, PA, with a location in Pune, India.